These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

426 related items for PubMed ID: 18512311

  • 41. Immunophenotypic characterization of leukemic stem cells in acute myeloid leukemia using single tube 10-colour panel by multiparametric flow cytometry: Deciphering the spectrum, complexity and immunophenotypic heterogeneity.
    Das N, Panda D, Gajendra S, Gupta R, Thakral D, Kaur G, Khan A, Singh VK, Vemprala A, Bakhshi S, Seth R, Sahoo RK, Sharma A, Rai S, Prajapati VK, Singh S.
    Int J Lab Hematol; 2024 Aug; 46(4):646-656. PubMed ID: 38456256
    [Abstract] [Full Text] [Related]

  • 42. CD117/CD34 expression in leukemic blasts.
    Wells SJ, Bray RA, Stempora LL, Farhi DC.
    Am J Clin Pathol; 1996 Aug; 106(2):192-5. PubMed ID: 8712172
    [Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46. [In Vitro Identification and Characteristics of CD34- Leukemia Stem Cell in t(8;21) Acute Myeloid Leukemia].
    Zhang YH, Yang L, Wang YZ, Kong Y, Zhu HH, Qin YZ.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Oct; 25(5):1289-1294. PubMed ID: 29070097
    [Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49. Microfluidics for the detection of minimal residual disease in acute myeloid leukemia patients using circulating leukemic cells selected from blood.
    Jackson JM, Taylor JB, Witek MA, Hunsucker SA, Waugh JP, Fedoriw Y, Shea TC, Soper SA, Armistead PM.
    Analyst; 2016 Jan 21; 141(2):640-51. PubMed ID: 26523411
    [Abstract] [Full Text] [Related]

  • 50. High aldehyde dehydrogenase activity at diagnosis predicts relapse in patients with t(8;21) acute myeloid leukemia.
    Yang L, Chen WM, Dao FT, Zhang YH, Wang YZ, Chang Y, Liu YR, Jiang Q, Zhang XH, Liu KY, Huang XJ, Qin YZ.
    Cancer Med; 2019 Sep 21; 8(12):5459-5467. PubMed ID: 31364309
    [Abstract] [Full Text] [Related]

  • 51. A simple one-tube assay for immunophenotypical quantification of leukemic stem cells in acute myeloid leukemia.
    Zeijlemaker W, Kelder A, Oussoren-Brockhoff YJ, Scholten WJ, Snel AN, Veldhuizen D, Cloos J, Ossenkoppele GJ, Schuurhuis GJ.
    Leukemia; 2016 Feb 21; 30(2):439-46. PubMed ID: 26437777
    [Abstract] [Full Text] [Related]

  • 52. Prognostic value of multicenter flow cytometry harmonized assessment of minimal residual disease in acute myeloblastic leukemia.
    Lacombe F, Campos L, Allou K, Arnoulet C, Delabarthe A, Dumezy F, Feuillard J, Geneviève F, Guérin E, Guy J, Jouault H, Lepelley P, Maynadié M, Solly F, Ballon OW, Preudhomme C, Baruchel A, Dombret H, Ifrah N, Béné MC, Groupe d'Etude Immunologique des Leucémies (GEIL).
    Hematol Oncol; 2018 Apr 21; 36(2):422-428. PubMed ID: 29218734
    [Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54. Leukemic stem cell frequency: a strong biomarker for clinical outcome in acute myeloid leukemia.
    Terwijn M, Zeijlemaker W, Kelder A, Rutten AP, Snel AN, Scholten WJ, Pabst T, Verhoef G, Löwenberg B, Zweegman S, Ossenkoppele GJ, Schuurhuis GJ.
    PLoS One; 2014 Apr 21; 9(9):e107587. PubMed ID: 25244440
    [Abstract] [Full Text] [Related]

  • 55. The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells.
    van Rhenen A, van Dongen GA, Kelder A, Rombouts EJ, Feller N, Moshaver B, Stigter-van Walsum M, Zweegman S, Ossenkoppele GJ, Jan Schuurhuis G.
    Blood; 2007 Oct 01; 110(7):2659-66. PubMed ID: 17609428
    [Abstract] [Full Text] [Related]

  • 56. [Determination of leukemia stem cells in childhood acute myeloid leukemia and its clinical significance].
    Wang D, Tang YM, Xu XJ, Shen HQ, Qian BQ.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Aug 01; 18(4):952-8. PubMed ID: 20723307
    [Abstract] [Full Text] [Related]

  • 57. Delineation of target expression profiles in CD34+/CD38- and CD34+/CD38+ stem and progenitor cells in AML and CML.
    Herrmann H, Sadovnik I, Eisenwort G, Rülicke T, Blatt K, Herndlhofer S, Willmann M, Stefanzl G, Baumgartner S, Greiner G, Schulenburg A, Mueller N, Rabitsch W, Bilban M, Hoermann G, Streubel B, Vallera DA, Sperr WR, Valent P.
    Blood Adv; 2020 Oct 27; 4(20):5118-5132. PubMed ID: 33085758
    [Abstract] [Full Text] [Related]

  • 58. [Clinical significance of CD34(+)CD38(+) and CD34(+)CD38(low/-) subgroups in bone marrow of patients with B lymphoblastic leukemia].
    Hao L, Liu YR, Wang YZ, Chang Y, Qin YZ, Li JL, Li LD, Huang XJ.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Aug 27; 20(4):801-5. PubMed ID: 22931632
    [Abstract] [Full Text] [Related]

  • 59. High prognostic value of minimal residual disease detected by flow-cytometry-enhanced fluorescence in situ hybridization in core-binding factor acute myeloid leukemia (CBF-AML).
    Wang L, Gao L, Xu S, Gong S, Liu M, Qiu H, Xu X, Ni X, Chen L, Lu S, Chen J, Song X, Zhang W, Yang J, Hu X, Wang J.
    Ann Hematol; 2014 Oct 27; 93(10):1685-94. PubMed ID: 24844781
    [Abstract] [Full Text] [Related]

  • 60. hMICL and CD123 in combination with a CD45/CD34/CD117 backbone - a universal marker combination for the detection of minimal residual disease in acute myeloid leukaemia.
    Roug AS, Larsen HØ, Nederby L, Just T, Brown G, Nyvold CG, Ommen HB, Hokland P.
    Br J Haematol; 2014 Jan 27; 164(2):212-22. PubMed ID: 24152218
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 22.